News //

New perspectives for the diagnosis and treatment of cisplatin-resistant pediatric liver cancers

Duchenne Muscular Dystrophy
Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer

IntegraGen is delighted to share this new publication on tumor plasticity and cisplatin resistance in pediatric liver cancers. Sequencing services (WES, RNA-seq, snRNA-seq, RRBS) and expertise support, particularly for single nuclei RNA-seq experiment, (…)  » 

News //

Technical Brief: Low-Pass Whole Genome Sequencing – Getting more from less

LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background

Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…)  » 

News //

What’s new with MERCURY?

Our latest release: MERCURY™ v3.0

We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience.

MERCURY v3.0 has (…)  » 

News //

IntegraGen Achieves CE Mark for Its MERCURY™ Cloud-based Software Tool Which Supports Molecular Tumor Profiling for Cancer Patients

IntegraGen announces the company’s MERCURY cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…)  » 

News //

IntegraGen Update – Still open to meet your research needs

IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.

We have undertaken (…)  »